- 米国企業
- BIOCRYST PHARMACEUTICALS INC
BIOCRYST PHARMACEUTICALS INCBCRX
時価総額
PER
| 2011年 12月31日 | 2012年 12月31日 | 2013年 12月31日 | 2014年 12月31日 | 2015年 12月31日 | 2016年 12月31日 | 2017年 12月31日 | 2018年 12月31日 | 2019年 12月31日 | 2020年 12月31日 | 2021年 12月31日 | 2022年 12月31日 | 2023年 12月31日 | |
| Product | - | - | - | - | - | - | - | - | 18 | 3 | 136 | 268 | 325 |
| Royalty revenue | - | - | - | - | - | - | - | 6 | 6 | 3 | -0 | 3 | 2 |
| Milestone revenue | - | - | - | - | - | - | - | - | - | - | 15 | - | - |
| Collaborative and other research and development | - | - | - | - | - | - | - | 16 | 25 | 11 | 6 | 0 | 7 |
| Revenues | - | - | - | - | - | - | - | 21 | 49 | 18 | 157 | 271 | 331 |
| Cost of product sales | - | - | - | - | - | - | - | - | 4 | 2 | 7 | 6 | 4 |
| Research and development | 57 | 51 | 43 | 52 | 73 | 61 | 67 | 85 | 107 | 123 | 209 | 253 | 217 |
| Selling, general and administrative | - | - | - | - | 13 | 11 | 14 | 30 | 37 | 68 | 119 | 159 | 214 |
| Royalty | - | - | - | - | - | - | - | - | - | - | 0 | 0 | - |
| Royalty | - | - | - | - | - | - | - | - | - | - | - | - | 0 |
| Total operating expenses | 69 | 60 | 48 | 59 | 88 | 75 | 83 | 115 | 148 | 193 | 335 | 419 | 435 |
| Loss from operations | -50 | -34 | -31 | -46 | -39 | -49 | -57 | -94 | -99 | -175 | -178 | -148 | -104 |
| Interest and other income | - | - | - | - | - | - | - | - | - | 9 | 0 | 5 | 16 |
| Interest expense | 4 | 5 | 5 | 5 | 5 | 6 | 9 | 9 | 12 | 15 | 59 | 99 | 108 |
| (Loss) gain on extinguishment of debt | - | - | - | - | - | - | - | - | - | -2 | 56 | - | -29 |
| Foreign currency losses, net | -4 | -1 | 5 | 5 | 1 | -1 | -1 | -0 | 1 | -1 | -1 | -2 | -1 |
| Loss before income taxes | - | - | - | - | - | - | - | - | - | - | -182 | -244 | -226 |
| Income tax expense | - | - | - | - | - | - | - | - | - | - | 2 | 3 | 0 |
| Net loss | -57 | -39 | -30 | -45 | -43 | -55 | -66 | -101 | -109 | -183 | -184 | -247 | -227 |
| Foreign currency translation adjustment | - | - | - | - | - | - | - | - | - | - | 0 | 1 | 0 |
| Unrealized gain (loss) on available for sale investments | - | -0 | -0 | -0 | -0 | 0 | -0 | -0 | 0 | -0 | -0 | -1 | 1 |
| Net comprehensive loss | - | -39 | -30 | -45 | -43 | -55 | -66 | -101 | -109 | -183 | -184 | -247 | -225 |
| Earnings Per Share, Basic | - | - | - | - | - | - | - | - | - | - | - | -1.33 | -1.18 |
| Earnings Per Share, Diluted | - | - | - | - | - | - | - | - | - | - | - | -1.33 | -1.18 |
| Product | - | - | - | - | - | - | - | - | 18 | 3 | 136 | 268 | 325 |
| Royalty revenue | - | - | - | - | - | - | - | 6 | 6 | 3 | -0 | 3 | 2 |
| Milestone revenue | - | - | - | - | - | - | - | - | - | - | 15 | - | - |
| Collaborative and other research and development | - | - | - | - | - | - | - | 16 | 25 | 11 | 6 | 0 | 7 |
| Revenues | - | - | - | - | - | - | - | 21 | 49 | 18 | 157 | 271 | 331 |
| Cost of product sales | - | - | - | - | - | - | - | - | 4 | 2 | 7 | 6 | 4 |
| Research and development | 57 | 51 | 43 | 52 | 73 | 61 | 67 | 85 | 107 | 123 | 209 | 253 | 217 |
| Selling, general and administrative | - | - | - | - | 13 | 11 | 14 | 30 | 37 | 68 | 119 | 159 | 214 |
| Royalty | - | - | - | - | - | - | - | - | - | - | 0 | 0 | - |
| Royalty | - | - | - | - | - | - | - | - | - | - | - | - | 0 |
| Total operating expenses | 69 | 60 | 48 | 59 | 88 | 75 | 83 | 115 | 148 | 193 | 335 | 419 | 435 |
| Loss from operations | -50 | -34 | -31 | -46 | -39 | -49 | -57 | -94 | -99 | -175 | -178 | -148 | -104 |
| Interest and other income | - | - | - | - | - | - | - | - | - | 9 | 0 | 5 | 16 |
| Interest expense | 4 | 5 | 5 | 5 | 5 | 6 | 9 | 9 | 12 | 15 | 59 | 99 | 108 |
| (Loss) gain on extinguishment of debt | - | - | - | - | - | - | - | - | - | -2 | 56 | - | -29 |
| Foreign currency losses, net | -4 | -1 | 5 | 5 | 1 | -1 | -1 | -0 | 1 | -1 | -1 | -2 | -1 |
| Loss before income taxes | - | - | - | - | - | - | - | - | - | - | -182 | -244 | -226 |
| Income tax expense | - | - | - | - | - | - | - | - | - | - | 2 | 3 | 0 |
| Net loss | -57 | -39 | -30 | -45 | -43 | -55 | -66 | -101 | -109 | -183 | -184 | -247 | -227 |
| Foreign currency translation adjustment | - | - | - | - | - | - | - | - | - | - | 0 | 1 | 0 |
| Unrealized gain (loss) on available for sale investments | - | -0 | -0 | -0 | -0 | 0 | -0 | -0 | 0 | -0 | -0 | -1 | 1 |
| Net comprehensive loss | - | -39 | -30 | -45 | -43 | -55 | -66 | -101 | -109 | -183 | -184 | -247 | -225 |
| Earnings Per Share, Basic | - | - | - | - | - | - | - | - | - | - | - | -1.33 | -1.18 |
| Earnings Per Share, Diluted | - | - | - | - | - | - | - | - | - | - | - | -1.33 | -1.18 |